Drug class
The phrase "Intermediate-, Long-acting, and Combination Insulins" functions as a compendial and formulary classification category rather than a single distinct molecular class. Read more about Intermediate-, Long-acting, and Combination Insulins
87 drugs in this class 12 manufacturers
The phrase "Intermediate-, Long-acting, and Combination Insulins" functions as a compendial and formulary classification category rather than a single distinct molecular class.
It encompasses intermediate-acting insulins (such as NPH), long- or ultra-long-acting basal insulin analogs (such as glargine, detemir, and degludec), fixed-ratio premixed insulins, and combinations with non-insulin injectables.
These agents mimic physiological basal pancreatic insulin secretion, stimulate cellular glucose uptake, and suppress hepatic gluconeogenesis to maintain glycemic control over extended periods or across both fasting and postprandial states.
Clinically, these formulations are primarily indicated for the management of type 1 diabetes mellitus, type 2 diabetes mellitus, and gestational diabetes.
The phrase "Intermediate-, Long-acting, and Combination Insulins" functions as a compendial and formulary classification category rather than a single distinct molecular class
It encompasses intermediate-acting insulins (such as NPH), long- or ultra-long-acting basal insulin analogs (such as glargine, detemir, and degludec), fixed-ratio premixed insulins, and combinations with non-insulin injectables
It encompasses intermediate-acting insulins (such as NPH), long- or ultra-long-acting basal insulin analogs (such as glargine, detemir, and degludec), fixed-ratio premixed insulins, and combinations with non-insulin injectables
It encompasses intermediate-acting insulins (such as NPH), long- or ultra-long-acting basal insulin analogs (such as glargine, detemir, and degludec), fixed-ratio premixed insulins, and combinations with non-insulin injectables
These agents mimic physiological basal pancreatic insulin secretion, stimulate cellular glucose uptake, and suppress hepatic gluconeogenesis to maintain glycemic control over extended periods or across both fasting and postprandial states Clinically, these formulations are primarily indicated for the management of type 1 diabetes mellitus, type 2 diabetes mellitus, and gestational diabetes
These agents mimic physiological basal pancreatic insulin secretion, stimulate cellular glucose uptake, and suppress hepatic gluconeogenesis to maintain glycemic control over extended periods or across both fasting and postprandial states
These agents mimic physiological basal pancreatic insulin secretion, stimulate cellular glucose uptake, and suppress hepatic gluconeogenesis to maintain glycemic control over extended periods or across both fasting and postprandial states
Clinically, these formulations are primarily indicated for the management of type 1 diabetes mellitus, type 2 diabetes mellitus, and gestational diabetes
Following a drug class requires a free Physicians Office Resource account.
